The company's diagnostic test uses targeted genomic sequencing to measure the concentration of genetic biomarkers in circulation, allowing for the simultaneous staging of fibrosis and the distinction between benign and severe liver disease. By identifying the patterns of early tumorigenesis, the test provides patients with an accurate depiction of their health. AGE Diagnostics was founded in 2021 and is based in Washington, D.C.